GlassScriptPhysician profile
Selena M De Leon
NPI 1578234621
$2,989.05
in general payments reported to CMS, 2019-2025
31 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $863 · 2023: $930 · 2024: $792 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $663.60 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $389.90 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $312.68 | 2022-2025 | |
| Organon LLC | $174.08 | 2022 | |
| Pfizer INC. | $110.80 | 2023-2025 | |
| Amgen INC. | $105.11 | 2022-2024 | Otezla, Repatha, Evenity |
| Teva Pharmaceuticals USA, INC. | $104.87 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $102.60 | 2022-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $88.41 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $86.69 | 2021-2023 | Gattex |
| Lundbeck LLC | $85.12 | 2024 | Rexulti |
| Endo Pharmaceuticals INC. | $84.00 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.28 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.01 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $70.56 | 2022-2023 | Steglatro, Belsomra, Steglujan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $64.16 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $60.24 | 2023-2025 | Livalo, Zoryve, Seglentis |
| Ibsa Pharma INC. | $42.02 | 2023 | Tirosint, Licart |
| Ironwood Pharmaceuticals, INC | $36.47 | 2021-2022 | |
| Ardelyx, INC. | $34.75 | 2024-2025 | Ibsrela |
| Ambu INC. | $26.33 | 2022 | |
| Currax Pharmaceuticals LLC | $23.79 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $23.30 | 2024 | Rexulti |
| Ucb, INC. | $20.50 | 2024 | Rystiggo |
| E.R. Squibb & Sons, L.L.C. | $19.85 | 2023 | Eliquis |
| Sanofi Pasteur INC. | $19.73 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.06 | 2024 | |
| Antares Pharma, INC. | $18.81 | 2024 | Xyosted |
| Astellas Pharma US INC | $16.37 | 2025 | Veozah |
| Agios Pharmaceuticals, INC. | $14.06 | 2023 | Pyrukynd |
| Exact Sciences Corporation | $13.90 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selena De Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.